PeterLabs Holdings (0171) Fair Value & Analysis
Healthcare · MY · Market cap 64.7M MYR
Fair value as of: Jun 24, 2026
Analysis
PeterLabs Holdings (0171) currently trades at 0.2450 MYR, while our model-based Fair Value estimate is 0.1900 MYR — implying the stock looks roughly 22.4% overvalued today. We read business quality at 92/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
About the company
PeterLabs Holdings Berhad, an investment holding company, engages in manufacturing, distribution, trading, and export of animal health and nutrition products in Malaysia and internationally. The company operates through three segments: Manufacturing, Trading, and Others. It offers biosecurity products and disinfectants, compound feed supplements, feed additives, nutritional premixes, pharmaceuticals, and water-soluble supplements. The company also engages in the distribution of consumer goods, including home care, oral care, baby care, and feminine care products, as well as grain products, and processed foods and beverage products to retailers, such as supermarkets, mini markets, sundry shops, convenience stores, pharmacies, petrol kiosks, Chinese medical halls, and hardware stores. The company was founded in 2002 and is headquartered in Nilai, Malaysia.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is PeterLabs Holdings (0171) undervalued?
What is the fair value of 0171?
What is the quality score of 0171?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.